A randomized, double-blind, single-dose, two-arm, parallel study comparing pharmacokinetics, immunogenicity and tolerability of branded adalimumab and its biosimilar LBAL in healthy male volunteers
2017 ◽
Vol 26
(5)
◽
pp. 619-624
◽
Keyword(s):